ZAGENO on Growth Trajectory - Startup Becoming #1 Online Marketplace for Life Science Research Products; Raises $8 Million
BOSTON, Mass., USA, and BERLIN, GERMANY, Oct. 25, 2017 (GLOBE NEWSWIRE) -- ZAGENO Inc., announces successful Series A investment of $8 Million US Dollars led by Capnamic Ventures, with Grazia Equity, lead investor in the seed round, also investing. The investment will be used to fuel growth in the key markets USA and Europe, by ramping up sales, marketing, and technical integration teams.
ZAGENO Launching a New Era of Digital Science and Research
"Just two years old, we are experiencing enormous traction, where global leaders in life science research, such as The Babraham Institute, choose to purchase life science research products through us," said Co-Founder and CEO of ZAGENO David Pumberger. "There is a vast need for digitalization in science and research! We founded ZAGENO with the vision of connecting scientists, administrative departments, and vendors of biotechnology products via one single platform, thereby creating a WIN-WIN-WIN-Situation for everybody involved. Nobody has dared to do that so far," he continued.
What is the WIN-WIN-WIN-situation for scientists, academic research institutes, researching companies, and equipment vendors? For the first time, ZAGENO enables scientists in their laboratories to choose crucial products directly via an online marketplace, from an extensive and high-quality product portfolio. Currently, researchers from 250+ leading research institutions in the U.S. and Europe compare products every day on ZAGENO for their experiments and order directly from across 650+ different vendors. This newly unveiled transparency is an absolute novelty in the biotech industry and saves costs as well as time for researchers.
ZAGENO enables straightforward integration of ordering and purchasing processes into existing software systems. And it is a milestone in the direction of bundled, and therefore, more-efficient, operation flows for academic research institutes and research companies alike. Biotechnology vendors benefit from the ZAGENO online-platform by reaching potential customers right at the buying/decision-making moments. They can also leverage ZAGENO as an additional digital sales channel to increase their reach in the key markets - USA and Europe. Further, the ZAGENO online-platform represents a valuable marketing tool to strengthen brand awareness and foster brand image and thus helps industry players to adapt to existing e-commerce models by increased customer service and content quality.
Commenting on The Babraham Institute's experience with ZAGENO, Michael Norden, the Institute's head of purchasing, said, "ZAGENO enables our 200+ scientists to choose and order life science research products from all vendors using one platform. This further streamlines our purchasing processes and allows us to gain full transparency on our spending. Ultimately, scientists focus on their research while complying with all purchasing requirements. We have found ZAGENO's customer service to be outstanding."
"ZAGENO combines an exceptional team and is the first to unlock an untapped billion dollar U.S. market," said Capnamic Ventures General Partner Christian Siegele.
Founding Partner of Grazia Equity Alec Rauschenbusch commented, "ZAGENO is fantastic. It's a true game-changer, helping the life science industry become more successful."
ZAGENO's Pumberger added, "Together with our partners and the Series A funding, we will strengthen our position at the interface of technology and biotech, as well as reach our targeted growth in focus markets. We feel very fortunate to grow together with Capnamic Ventures and Grazia Equity and to benefit from their deep industry connections and insights. Consistent with entrepreneurial values, mindsets, and growth targets, we focus on fulfilling customers' needs on all sides of the platform!"
About Capnamic Ventures
Capnamic Ventures (www.capnamic.com) is one of Europe's leading early-stage Venture Capital firms, with offices in Berlin and Cologne. The VC invests most of its funds in tech startups in the German-speaking region. Capnamic also joins forces with international co-investors. All portfolio companies are supported through Capnamic's global network of investors and industry partners.
The vast expertise of the Capnamic team includes more than 70 investments, a high turnover of successful trade sales and IPOs, as well as a strong entrepreneurial track record within the investment team. The general partners are Jörg Binnenbrücker (@bibrue), Olaf Jacobi (@olafjacobi) and Christian Siegele.
For more details, visit capnamic.com or @Capnamic on Twitter.
About Grazia Equity
Grazia Equity, one of Germany's top venture capital firms, has been supporting a large number of mostly young companies, often from their foundation to the Initial Public Offering or eventual sale. Grazia's success derives from a partnership with extraordinarily strong entrepreneurial teams to turn them into international market leaders. In contrast to other venture capital firms Grazia has a solid permanent capital structure ("Evergreen"). Grazia's portfolio companies profit from the entrepreneurial background and the business development expertise of its partner team as well as a far-reaching international network. Being active in Germany, Europe and in the USA Grazia has invested early in category leaders such as Statista, Mister Spex, Conergy, Quantenna, and Yeay.
For more information, please visit grazia.com
About ZAGENO Inc.
Since its formation in 2015, ZAGENO Inc. sets new standards in the international biotech market. With the vision to offer an online marketplace connecting scientists, academic research institutes, and biotech manufacturers, ZAGENO grows exponentially and represents a milestone for the digitization of science and research. World-renowned research facilities use ZAGENO for ordering lab equipment and for optimizing internal processes. The start-up employs 35 staff members in Boston (USA) and Berlin (Germany). These two locations were selected to be close to centers known for research advancements and scientific breakthroughs. For more "EUREKA"-moments - welcome to ZAGENO: https://zageno.com/
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/8f25a44f-43ac-4555-89c9-88e214485457
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/4121b588-dce2-4b4c-81f5-1375ea13b05b
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/b62c1ccf-4885-4563-813c-5f4596194fd2
Media Contact: Caroline Grossman
Company Contact: Florian Wegener, MD, PhD, MBA, Chief Revenue Officer
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ZAGENO, Inc. via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
Resverlogix Provides Unrestricted Educational Grant for Epigenetic Symposium at International Renal Congress25.5.2018 07:45 | Pressemelding
CALGARY, Alberta, May 24, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announced that on Friday, May 25, 2018, at the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Congress in Copenhagen, Denmark, the Company is supporting a symposium titled: "Epigenetics in CKD & CVD: A potential breakthrough therapy?" The symposium highlights the role of epigenetics and BET-inhibition in chronic kidney disease and cardiovascular disease, especially in patients with diabetes mellitus, and the significant unmet need that still exists in this patient population. The symposium is co-chaired by Vincent M. Brandenburg, MD - Nephrologist, Aachen, Germany and Kamyar Kalantar-Zadeh, MD - UC Irvine School of Medicine, Irvine, CA, USA, both leading scientists also serving as advisors to Resverlogix's Renal program. The speakers and agenda are as follows: Introduction Vincent M. Brandenburg, MD - University Hospital of the RWTH
Atico Reports Consolidated Financial Results for the First Quarter of 201824.5.2018 22:30 | Pressemelding
(All amounts expressed in US dollars, unless otherwise stated) VANCOUVER, British Columbia, May 24, 2018 (GLOBE NEWSWIRE) -- Atico Mining Corporation (the "Company" or "Atico") (TSX.V:ATY) (OTC:ATCMF) today announced its financial results for the three months ended March 31, 2018, posting a net income of $0.4 million. Fernando E. Ganoza, CEO and Director, commented, "The strong production and all-in sustaining cash cost of $1.85 achieved this quarter is not reflected in the financial results as a large concentrate shipment was delayed to the second quarter, along with the revenue associated with those tonnes. The shipping schedule is expected to stabilize during the second quarter, where we will then benefit from the additional shipped concentrate and recognized revenue. We anticipate strong financial results in the next quarter." Mr. Ganoza continued, "Our emphasis will continue to be on further strengthening our balance sheet, improving production costs and most importantly regional
Luxembourg Announced as SNOMED International's Newest Member24.5.2018 15:16 | Pressemelding
London, United Kingdom, May 24, 2018 (GLOBE NEWSWIRE) -- SNOMED International and Agence eSanté Luxembourg are pleased to announce that Luxembourg has joined the organization as its thirty-second Member. Luxembourg, one of the leading nations in the area of information and communication technology, has set the development of eHealth technologies as a high priority. Agence eSanté, Luxembourg's national agency for the exchange and sharing of medical data, has set an overall mission to facilitate clinical information exchange both within Luxembourg and across other international actors. To work towards this reality, the agency has taken part in discussions about standardization across Europe, a contributing building block achieved with its membership in SNOMED International. With their membership, Agence eSanté has committed their support for the use of structured clinical terminology. When applied to the health sector, interoperability ensures that information systems, and through them h
SEMAFO Signs Underground Mining Services Contract with AUMS24.5.2018 14:00 | Pressemelding
MONTREAL, May 24, 2018 (GLOBE NEWSWIRE) -- SEMAFO Inc. (TSX:SMF) (OMX:SMF) reports that it has signed a mining services contract with African Underground Mining Services ("AUMS") to provide turnkey mining services for Siou underground. AUMS is a well-known and reputable mining contractor with underground experience in Burkina Faso and across Africa. Under the mining services contract, AUMS will be responsible for supplying the mining fleet and a skilled labour force for Siou underground in addition to ensuring development, production and auxiliary services. SEMAFO will provide technical services including geology and engineering as well as leveraging the existing surface infrastructure at Mana. The mining services contract has a term of 70 months. The economic terms of the mining services contract are consistent with the economics presented in the Mana pre-feasibility study filed March 29, 2018 on SEDAR. Preparatory work has already commenced on Siou underground with full project deplo
Merus Announces First Patient Dosed in Phase 1 Clinical Trial of MCLA-158 in Patients with Solid Tumors24.5.2018 13:00 | Pressemelding
- IND Accepted in April by the U.S. FDA for MCLA-158 - UTRECHT, The Netherlands, May 24, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the first patient has been dosed in a Phase 1, first-in human clinical trial of MCLA-158 in patients with solid tumors with an initial focus on metastatic colorectal cancer. The trial will be conducted in Europe, where several Clinical Trial Applications (CTAs) have been approved to date. The Company also announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for MCLA-158, which was accepted by the FDA in April 2018. With this acceptance, Merus plans to open additional sites for this trial in the United States. MCLA-158 is designed to bind to cancer stem cells expressing leucine-rich repeat-containing G protein-coupled receptor 5 (Lgr5) and epidermal grow
PRA Named International Clinical Research Company of the Year24.5.2018 10:00 | Pressemelding
RALEIGH, N.C., May 24, 2018 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) is pleased to announce it was recognized by PharmaTimes as the International Clinical Research Company of the Year. This is the fifth year in a row that PRA has received this award. "This award celebrates excellence in the clinical research industry and we are honored to once again be recognized by our peers," said Colin Shannon, President and Chief Executive Officer. "This award is possible thanks to the incredibly talented PRA team members we have working around the world who are deeply committed to their work in bringing new and life-saving therapies to the patients who need them." PRA also swept the Clinical Research Associate and Clinical Trial Administrator categories capturing a total of 11 awards. These awards follow PRA's recognition earlier this month in the PharmaTimes Americas competition where PRA also received 11 awards, including Company of the Year. The PharmaTimes, International Cli
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom